CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Jeffrey E Lancet; Geoffrey L Uy; Laura F Newell; Tara L Lin; Ellen K Ritchie; Robert K Stuart; Stephen A Strickland; Donna Hogge; Scott R Solomon; Dale L Bixby; Jonathan E Kolitz; Gary J Schiller; Matthew J Wieduwilt; Daniel H Ryan; Stefan Faderl; Jorge E Cortes

doi:10.1016/s2352-3026(21)00134-4

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00134-4 ◽

2021 ◽

Vol 8 (7) ◽

pp. e481-e491

Author(s):

Jeffrey E Lancet ◽

Geoffrey L Uy ◽

Laura F Newell ◽

Tara L Lin ◽

Ellen K Ritchie ◽

...

Keyword(s):

Older Adults ◽

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Acute Myeloid

Download Full-text

Faculty Opinions recommendation of Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958906.793462914 ◽

2012 ◽

Author(s):

Nelson Chao

Keyword(s):

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Reduced Intensity Conditioning ◽

Open Label ◽

Phase 3 ◽

First Complete Remission ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Cited By ~ 191

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70152-9 ◽

2013 ◽

Vol 14 (7) ◽

pp. 599-608 ◽

Cited By ~ 55

Author(s):

Jie Jin ◽

Jian-Xiang Wang ◽

Fei-Fei Chen ◽

De-Pei Wu ◽

Jiong Hu ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

De Novo ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30150-0 ◽

2019 ◽

Vol 20 (7) ◽

pp. 984-997 ◽

Cited By ~ 79

Author(s):

Jorge E Cortes ◽

Samer Khaled ◽

Giovanni Martinelli ◽

Alexander E Perl ◽

Siddhartha Ganguly ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Salvage Chemotherapy ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

The Lancet Haematology ◽

10.1016/s2352-3026(19)30114-0 ◽

2019 ◽

Vol 6 (9) ◽

pp. e480-e488 ◽

Cited By ~ 19

Author(s):

Farhad Ravandi ◽

Rita Assi ◽

Naval Daver ◽

Christopher B Benton ◽

Tapan Kadia ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

Acute Myeloid

Download Full-text

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30455-1 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1201-1212 ◽

Cited By ~ 5

Author(s):

Li Xuan ◽

Yu Wang ◽

Fen Huang ◽

Zhiping Fan ◽

Yajing Xu ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Haematopoietic Stem Cell Transplantation ◽

Haematopoietic Stem Cell ◽

Open Label ◽

Phase 3 ◽

Acute Myeloid

Download Full-text

Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.073 ◽

2017 ◽

Vol 17 ◽

pp. S287

Author(s):

Jonathan Kolitz ◽

Stephen Strickland ◽

Jorge Cortes ◽

Donna Hogge ◽

Jeffrey Lancet ◽

...

Keyword(s):

Older Adults ◽

Overall Survival ◽

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

Phase 3 ◽

Acute Myeloid

Download Full-text

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00200-4 ◽

2015 ◽

Vol 16 (15) ◽

pp. 1525-1536 ◽

Cited By ~ 86

Author(s):

Alessandro Rambaldi ◽

Anna Grassi ◽

Arianna Masciulli ◽

Cristina Boschini ◽

Maria Caterina Micò ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Preparative Regimen ◽

Haemopoietic Stem Cell Transplantation ◽

Acute Myeloid

Download Full-text

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70349-2 ◽

2012 ◽

Vol 13 (10) ◽

pp. 1035-1044 ◽

Cited By ~ 144

Author(s):

Martin Bornhäuser ◽

Joachim Kienast ◽

Rudolf Trenschel ◽

Andreas Burchert ◽

Ute Hegenbart ◽

...

Keyword(s):

Complete Remission ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Reduced Intensity Conditioning ◽

Open Label ◽

Phase 3 ◽

First Complete Remission ◽

Reduced Intensity ◽

Acute Myeloid

Download Full-text

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(12)60485-1 ◽

2012 ◽

Vol 379 (9825) ◽

pp. 1508-1516 ◽

Cited By ~ 489

Author(s):

Sylvie Castaigne ◽

Cécile Pautas ◽

Christine Terré ◽

Emmanuel Raffoux ◽

Dominique Bordessoule ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

De Novo ◽

Gemtuzumab Ozogamicin ◽

Adult Patients ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Acute Myeloid

Download Full-text